An expert opinion statement, addressing a critical gap in cardiac care for Duchenne muscular dystrophy – providing thorough recommendations for the initiation and titration of cardiac medications based on disease progression and patient response.
Partnership of cardiologists with gene transfer therapy prescribers is essential to identifing patient-specific considerations that might influence risk for adverse cardiac events.
What: Poster Session When: Friday, October 11 from 2:15-3:15 pm Dystrophinopathy in ACTION; Analysis of the first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective
29th Annual Congress of World Muscle Society- ACTION Abstracts Poster Session Read More »
Abstract Advanced Cardiac Therapies Improving Outcomes Network (ACTION) and Pediatric Heart Transplant Society (PHTS) convened a working group at the beginning of 2020 during the COVID-19 pandemic, with the aim
The results of an ACTION-wide survey of pediatric cardiology providers are detailed in the latest ACTION publication, Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD):
ACTION receives $2 million grant from Parent Project Muscular Dystrophy (PPMD) to expand muscular dystrophy focused research and quality improvement initiatives
IMPROVING STROKE OUTCOMES IN CHILDREN SUPPORTED WITH A VENTRICULAR ASSIST DEVICE IN A QUALITY IMPROVEMENT NETWORK ACTION has been working to reduce the frequency of stroke associated with pediatric VAD
ABCs of Stroke Prevention Read More »
This ACTION article, published in Pediatric Transplantation, describes the results of ACTION’s November 2019 Waitlist Outcomes Committee (WOC) meeting. The WOC committee used improvement science methodology to develop a six-step
"*" indicates required fields
Copyright © 2024 Advanced Cardiac Therapies Improving Outcomes Network
